Novartis says rare muscle disease drug shows promise in early trial

Novartis said an experimental drug acquired in its $12 billion Avidity takeover showed promise in an early-to-mid-stage study for a genetic muscle disorder marked by slowly progressive muscle weakness. The update supports the strategic rationale for the deal and adds early clinical validation to the asset. The readout is encouraging but remains preliminary, so near-term market impact should be limited.

Analysis

Novartis said an experimental drug acquired in its $12 billion Avidity takeover showed promise in an early-to-mid-stage study for a genetic muscle disorder marked by slowly progressive muscle weakness. The update supports the strategic rationale for the deal and adds early clinical validation to the asset. The readout is encouraging but remains preliminary, so near-term market impact should be limited.